-
Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug
Wednesday, October 8, 2025 - 1:56pm | 585Read More...Zenas BioPharma Inc. (NASDAQ:ZBIO) and InnoCare Pharma Ltd. on Wednesday announced a license agreement granting Zenas global development and commercialization rights to orelabrutinib for multiple sclerosis and across all therapeutic areas other than oncology. ZBIO is delivering impressive returns....
